The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform
Nicole J. Look Hong - One of the best experts on this subject based on the ideXlab platform.
-
Lesional therapies for in-transit melanoma.
Journal of surgical oncology, 2020Co-Authors: Ashlie Nadler, Wadid Abadir, Nicole J. Look Hong, Nasrin Alavi, Frances C. WrightAbstract:To describe the outcomes of lesional therapy of in-transit melanoma (ITM) with interleukin-2 (IL-2), Diphencyprone (DPCP), combination lesional therapy (IL-2, retinoid, and imiquimod; CLT), and imiquimod. Data was collected for consecutive patients with ITM receiving lesional therapies from 2008 to 2018 in a retrospective review. Included patients did not have metastatic disease at time of starting on lesional therapy and were not on systemic therapy. The primary outcome was complete pathologic response (pCR). Of 83 patients, 57 (69%) started treatment with IL-2, 10 (12%) with DPCP, 12 (14%) with CLT, and 4 (5%) with imiquimod. pCR was achieved in 34 patients (41%) overall, including 44% starting on IL-2, 20% on DPCP, 58% on CLT, and none on imiquimod (P = .024). With a median follow-up of 45 months, cumulative one-year overall survival was 86%, with the best survival in the CLT group. Forty-eight percent experienced common terminology criteria for adverse events grade 1 or 2 toxicity. A quarter of patients on DPCP discontinued therapy due to toxicity (P = .002). IL-2 may be considered for the treatment of ITM with multiple or rapidly developing lesions where there would otherwise be significant morbidity with surgery, given pCR rates and toxicity. © 2020 Wiley Periodicals LLC.
-
Topical immunotherapy with Diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Expert review of clinical immunology, 2017Co-Authors: Carrie Yeung, Teresa M. Petrella, Wadid Abadir, Frances C. Wright, Nicole J. Look HongAbstract:ABSTRACTBackground: Diphencycprone (DPCP) is an immune contact sensitizer applied to melanoma lesions. Early studies show favorable efficacy. We present the first North-American series of patients treated with DPCP.Methods: A single center retrospective study of patients with in-transit or unresectable melanoma lesions treated with DPCP from December 1,2014 to December 31,2015 was completed. Primary objectives were response rate and toxicity. Secondary objective was health-related quality of life assessment with the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire.Results: Fifteen consecutive patients were identified with median age of 78 (range 43–92). 73% of patients had prior treatment. Two patients (13%) had a complete response after 25 and 32 weeks, respectively. Four patients (27%) had a partial response with a mean treatment time of 30 weeks (range 6–51 weeks). Six (40%) had stable disease. Six patients stopped DPCP – three from systemic progression and three from toxicity. T...
-
Topical immunotherapy with Diphencyprone (DPCP) for in-transit and other melanoma cutaneous lesions: Canadian single-institution case series.
Journal of Clinical Oncology, 2016Co-Authors: Carrie Yeung, Teresa M. Petrella, Wadid Abadir, Frances C. Wright, Nicole J. Look HongAbstract:e21071Background: In-transit melanoma metastases can have severe morbidity and poor survival. Preferred treatment is surgical resection but is limited by site and extent of disease. Diphencycprone ...
John F. Thompson - One of the best experts on this subject based on the ideXlab platform.
-
topical immunotherapy with Diphencyprone for in transit and cutaneously metastatic melanoma
Journal of Surgical Oncology, 2014Co-Authors: Diona L. Damian, Robyn P. M. Saw, John F. ThompsonAbstract:Topical Diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. To date, 50 patients have received DPCP therapy for at least 1 month at our institution, with complete clearance of cutaneous disease in 46% and partial response in a further 38% of patients. Topical immunotherapy with DPCP is inexpensive and well-tolerated and should be considered in patients with skin metastases unsuitable for or refractory to other forms of therapy. J. Surg. Oncol. 2014 109:308–313. © 2013 Wiley Periodicals, Inc.
-
Topical immunotherapy with Diphencyprone for in transit and cutaneously metastatic melanoma.
Journal of surgical oncology, 2013Co-Authors: Diona L. Damian, Robyn P. M. Saw, John F. ThompsonAbstract:Topical Diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. To date, 50 patients have received DPCP therapy for at least 1 month at our institution, with complete clearance of cutaneous disease in 46% and partial response in a further 38% of patients. Topical immunotherapy with DPCP is inexpensive and well-tolerated and should be considered in patients with skin metastases unsuitable for or refractory to other forms of therapy.
-
TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical Diphencyprone.
Journal of drugs in dermatology : JDD, 2010Co-Authors: Frank T. Martiniuk, Diona L. Damian, John F. Thompson, Richard A. Scolyer, Kam-meng Tchou-wong, William R. LevisAbstract:The authors provide an update on a previously reported patient with in-transit metastatic melanoma of the scalp treated with topical Diphencyprone (DPCP). Molecular studies implicate the thymus-derived TH17 lymphocyte subset in a remarkable immunotherapeutic regression. The authors performed RT-PCR of total RNA from paraffin-embedded tissue before and after treatment with DPCP. Before treatment with DPCP, the authors found elevated expression of IL 17C/D/E/F; after treatment there was no detectable expression. Conversely, increased expression of PLZF/CD27 and CTLA4 was seen after treatment with no expression before treatment. No expression of IL17A/B, CD7, RORgTand FoxP3 were before or after treatment. Conclusions are limited to only the time samples were obtained. Remarkable regression of an in-transit metastatic melanoma treated with the immunomodulatory agent DPCP showed gain and loss of gene expression of the TH17 pathway. Further study of this pathway from NK to NK-T to TH7 and TH1 cells both with and without accessory or dendritic cells will improve understanding of contact sensitizers as topical immunomodulators.
-
Topical Diphencyprone immunotherapy for cutaneous metastatic melanoma.
The Australasian journal of dermatology, 2009Co-Authors: Diona L. Damian, Robyn P. M. Saw, Kerwin Shannon, John F. ThompsonAbstract:Topical immunotherapy with contact sensitizers for metastatic melanoma was first reported more than 30 years ago. Diphencyprone (DPCP) immunotherapy is frequently used to treat cutaneous warts and alopecia areata, and we have previously reported the use of DPCP as a single agent to successfully treat extensive, radiotherapy-resistant melanoma metastases on the scalp. We now report DPCP treatment of a further six patients with cutaneous metastatic melanoma. Of seven patients treated with DPCP thus far, four have demonstrated complete responses of their cutaneous lesions and three have had partial responses. The treatment was well-tolerated by all patients. Topical immunotherapy with DPCP is inexpensive and relatively non-invasive and should be considered in patients with locally advanced skin metastases that are unsuitable for other therapies.
-
Treatment of extensive cutaneous metastatic melanoma with topical Diphencyprone
Journal of the American Academy of Dermatology, 2007Co-Authors: Diona L. Damian, John F. ThompsonAbstract:Diphencyprone is a potent contact sensitizer sometimes used to treat alopecia areata and cutaneous warts. A patient with previous primary nodular melanoma on the scalp developed extensive, confluent cutaneous metastases near the primary site, unsuitable for treatment with surgery or radiotherapy. Topical treatment with Diphencyprone as a single agent resulted in regression of all lesions, and the patient remains well 18 months later. Topical immunotherapy with Diphencyprone was an inexpensive and well-tolerated treatment for extensive cutaneous melanoma metastases in our patient unsuitable for other therapies.
Frances C. Wright - One of the best experts on this subject based on the ideXlab platform.
-
Lesional therapies for in-transit melanoma.
Journal of surgical oncology, 2020Co-Authors: Ashlie Nadler, Wadid Abadir, Nicole J. Look Hong, Nasrin Alavi, Frances C. WrightAbstract:To describe the outcomes of lesional therapy of in-transit melanoma (ITM) with interleukin-2 (IL-2), Diphencyprone (DPCP), combination lesional therapy (IL-2, retinoid, and imiquimod; CLT), and imiquimod. Data was collected for consecutive patients with ITM receiving lesional therapies from 2008 to 2018 in a retrospective review. Included patients did not have metastatic disease at time of starting on lesional therapy and were not on systemic therapy. The primary outcome was complete pathologic response (pCR). Of 83 patients, 57 (69%) started treatment with IL-2, 10 (12%) with DPCP, 12 (14%) with CLT, and 4 (5%) with imiquimod. pCR was achieved in 34 patients (41%) overall, including 44% starting on IL-2, 20% on DPCP, 58% on CLT, and none on imiquimod (P = .024). With a median follow-up of 45 months, cumulative one-year overall survival was 86%, with the best survival in the CLT group. Forty-eight percent experienced common terminology criteria for adverse events grade 1 or 2 toxicity. A quarter of patients on DPCP discontinued therapy due to toxicity (P = .002). IL-2 may be considered for the treatment of ITM with multiple or rapidly developing lesions where there would otherwise be significant morbidity with surgery, given pCR rates and toxicity. © 2020 Wiley Periodicals LLC.
-
Topical immunotherapy with Diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Expert review of clinical immunology, 2017Co-Authors: Carrie Yeung, Teresa M. Petrella, Wadid Abadir, Frances C. Wright, Nicole J. Look HongAbstract:ABSTRACTBackground: Diphencycprone (DPCP) is an immune contact sensitizer applied to melanoma lesions. Early studies show favorable efficacy. We present the first North-American series of patients treated with DPCP.Methods: A single center retrospective study of patients with in-transit or unresectable melanoma lesions treated with DPCP from December 1,2014 to December 31,2015 was completed. Primary objectives were response rate and toxicity. Secondary objective was health-related quality of life assessment with the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire.Results: Fifteen consecutive patients were identified with median age of 78 (range 43–92). 73% of patients had prior treatment. Two patients (13%) had a complete response after 25 and 32 weeks, respectively. Four patients (27%) had a partial response with a mean treatment time of 30 weeks (range 6–51 weeks). Six (40%) had stable disease. Six patients stopped DPCP – three from systemic progression and three from toxicity. T...
-
Topical immunotherapy with Diphencyprone (DPCP) for in-transit and other melanoma cutaneous lesions: Canadian single-institution case series.
Journal of Clinical Oncology, 2016Co-Authors: Carrie Yeung, Teresa M. Petrella, Wadid Abadir, Frances C. Wright, Nicole J. Look HongAbstract:e21071Background: In-transit melanoma metastases can have severe morbidity and poor survival. Preferred treatment is surgical resection but is limited by site and extent of disease. Diphencycprone ...
Marc Moncrieff - One of the best experts on this subject based on the ideXlab platform.
-
Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy
Annals of Surgical Oncology, 2021Co-Authors: Sophia Haywood, Jennifer Garioch, Arjun Ramaiya, Marc MoncrieffAbstract:Background Melanoma in-transit metastases (ITMs) are a challenge to treat and associated with systemic disease and poor prognosis. Topical Diphencyprone (DPCP), a potent contact sensitizer, is an established treatment for melanoma ITMs. This exploratory study investigated the utility of BRAF mutation status, CD8, PD-1, PD-L1, and TILs distribution as biomarkers for response of ITMs to topical immunotherapy (DPCP). Methods The ITM deposits of 40 patients treated with DPCP were subjected to biomarker analysis for BRAF status, CD8 and PD-1 expression on tumor-infiltrating lymphocytes (TILs), and tumor PD-L1 expression. Response to DPCP and overall survival (OS) were compared by biomarker status. Results After 12 weeks, 10 patients (25%) had a complete response, 12 patients (30%) had a partial response, and 18 patients (45%) had no response. No significant association was found between any individual biomarker and response to DPCP or OS. The BRAF mutation rate was 25% (10/40). All the patients with a complete response had BRAF wild-type tumor. Peritumoral CD8+ T-cells were associated with complete response ( P = 0.041). Both CD8+ and PD-1 expressions were highly correlated ( P
-
Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy.
Annals of surgical oncology, 2020Co-Authors: Sophia Haywood, Jennifer Garioch, Arjun Ramaiya, Marc MoncrieffAbstract:Melanoma in-transit metastases (ITMs) are a challenge to treat and associated with systemic disease and poor prognosis. Topical Diphencyprone (DPCP), a potent contact sensitizer, is an established treatment for melanoma ITMs. This exploratory study investigated the utility of BRAF mutation status, CD8, PD-1, PD-L1, and TILs distribution as biomarkers for response of ITMs to topical immunotherapy (DPCP). The ITM deposits of 40 patients treated with DPCP were subjected to biomarker analysis for BRAF status, CD8 and PD-1 expression on tumor-infiltrating lymphocytes (TILs), and tumor PD-L1 expression. Response to DPCP and overall survival (OS) were compared by biomarker status. After 12 weeks, 10 patients (25%) had a complete response, 12 patients (30%) had a partial response, and 18 patients (45%) had no response. No significant association was found between any individual biomarker and response to DPCP or OS. The BRAF mutation rate was 25% (10/40). All the patients with a complete response had BRAF wild-type tumor. Peritumoral CD8+ T-cells were associated with complete response (P = 0.041). Both CD8+ and PD-1 expressions were highly correlated (P
-
Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion
Journal of plastic reconstructive & aesthetic surgery : JPRAS, 2020Co-Authors: Jennifer Garioch, Marc MoncrieffAbstract:Summary Background In-transit metastases (ITMs) in melanoma are associated with poor prognosis, however a significant proportion of these patients survive for extended periods without further disease progression. We routinely use locoregional treatment e.g. Diphencyprone (DPCP) and/or isolated limb infusion (ILI) as long-term palliation. This study aimed to identify correct sequencing of these therapies based on disease burden and progression. Method Retrospective evaluation of all melanoma patients with ITMs treated with DPCP/ILI/both from 2010 to 2017 at our Cancer Centre was performed. Patients were initially assessed in a multidisciplinary setting and empirically prescribed DPCP for low-disease burden, ILI for high-disease burden. Patient demographics, tumour characteristics, response to therapy, ITM progression and patient outcomes were analysed. Results 78 patients (M:F = 30:48), aged 47–95years (median 74years) treated with DPCP/ILI/both (n = 44/21/13) were identified. Progression-free survival (PFS) was significantly increased in patients responsive to DPCP or ILI as initial treatment. Patients who failed on DPCP and subsequently treated with ILI had a significantly increased PFS compared to DPCP alone (p = 0.026, HR = 0.048). This was not the case with patients who were treated with DPCP following failed ILI. All patients who failed to respond to the initial therapy progressed within 6 months. Conclusion Our study shows that careful stratification ITM patients according to disease burden is fundamental to optimal outcomes. High-disease burden patients benefit from initial ILI; low-disease burden patients should commence on DPCP. ILI can be considered in DPCP patients who fail early. Systemic therapy should be considered when locoregional therapies fail after 12 months or after rapid relapse following ILI.
Diona L. Damian - One of the best experts on this subject based on the ideXlab platform.
-
topical immunotherapy with Diphencyprone for in transit and cutaneously metastatic melanoma
Journal of Surgical Oncology, 2014Co-Authors: Diona L. Damian, Robyn P. M. Saw, John F. ThompsonAbstract:Topical Diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. To date, 50 patients have received DPCP therapy for at least 1 month at our institution, with complete clearance of cutaneous disease in 46% and partial response in a further 38% of patients. Topical immunotherapy with DPCP is inexpensive and well-tolerated and should be considered in patients with skin metastases unsuitable for or refractory to other forms of therapy. J. Surg. Oncol. 2014 109:308–313. © 2013 Wiley Periodicals, Inc.
-
Topical immunotherapy with Diphencyprone for in transit and cutaneously metastatic melanoma.
Journal of surgical oncology, 2013Co-Authors: Diona L. Damian, Robyn P. M. Saw, John F. ThompsonAbstract:Topical Diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. To date, 50 patients have received DPCP therapy for at least 1 month at our institution, with complete clearance of cutaneous disease in 46% and partial response in a further 38% of patients. Topical immunotherapy with DPCP is inexpensive and well-tolerated and should be considered in patients with skin metastases unsuitable for or refractory to other forms of therapy.
-
TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical Diphencyprone.
Journal of drugs in dermatology : JDD, 2010Co-Authors: Frank T. Martiniuk, Diona L. Damian, John F. Thompson, Richard A. Scolyer, Kam-meng Tchou-wong, William R. LevisAbstract:The authors provide an update on a previously reported patient with in-transit metastatic melanoma of the scalp treated with topical Diphencyprone (DPCP). Molecular studies implicate the thymus-derived TH17 lymphocyte subset in a remarkable immunotherapeutic regression. The authors performed RT-PCR of total RNA from paraffin-embedded tissue before and after treatment with DPCP. Before treatment with DPCP, the authors found elevated expression of IL 17C/D/E/F; after treatment there was no detectable expression. Conversely, increased expression of PLZF/CD27 and CTLA4 was seen after treatment with no expression before treatment. No expression of IL17A/B, CD7, RORgTand FoxP3 were before or after treatment. Conclusions are limited to only the time samples were obtained. Remarkable regression of an in-transit metastatic melanoma treated with the immunomodulatory agent DPCP showed gain and loss of gene expression of the TH17 pathway. Further study of this pathway from NK to NK-T to TH7 and TH1 cells both with and without accessory or dendritic cells will improve understanding of contact sensitizers as topical immunomodulators.
-
Topical Diphencyprone immunotherapy for cutaneous metastatic melanoma.
The Australasian journal of dermatology, 2009Co-Authors: Diona L. Damian, Robyn P. M. Saw, Kerwin Shannon, John F. ThompsonAbstract:Topical immunotherapy with contact sensitizers for metastatic melanoma was first reported more than 30 years ago. Diphencyprone (DPCP) immunotherapy is frequently used to treat cutaneous warts and alopecia areata, and we have previously reported the use of DPCP as a single agent to successfully treat extensive, radiotherapy-resistant melanoma metastases on the scalp. We now report DPCP treatment of a further six patients with cutaneous metastatic melanoma. Of seven patients treated with DPCP thus far, four have demonstrated complete responses of their cutaneous lesions and three have had partial responses. The treatment was well-tolerated by all patients. Topical immunotherapy with DPCP is inexpensive and relatively non-invasive and should be considered in patients with locally advanced skin metastases that are unsuitable for other therapies.
-
Treatment of extensive cutaneous metastatic melanoma with topical Diphencyprone
Journal of the American Academy of Dermatology, 2007Co-Authors: Diona L. Damian, John F. ThompsonAbstract:Diphencyprone is a potent contact sensitizer sometimes used to treat alopecia areata and cutaneous warts. A patient with previous primary nodular melanoma on the scalp developed extensive, confluent cutaneous metastases near the primary site, unsuitable for treatment with surgery or radiotherapy. Topical treatment with Diphencyprone as a single agent resulted in regression of all lesions, and the patient remains well 18 months later. Topical immunotherapy with Diphencyprone was an inexpensive and well-tolerated treatment for extensive cutaneous melanoma metastases in our patient unsuitable for other therapies.